Synthos Research · updated weekly · graded in public

The Research Hub

Stock Deep Dives — 695 assets

Institutional-grade research on every S&P 500 company, curated growth names, and 76 crypto assets — scores, fair-value ranges, honest verdicts. Free and public.

Search tickers

See what a deep dive looks like

Eli Lilly and Company (LLY)Buy

Fair value ~$1,220

“"Eli Lilly is the purest listed expression of the house anchor thesis — metabolic disease as the master switch of chronic illness — and it is running the fastest large-cap revenue growth in this batch: +45.2% in FY2025 to $65.179B, +55.5% year-over-year in the first quarter of 2026, at an 83.8% gross margin. It is also the most concentrated business we cover: the 10-Q states that Mounjaro and Zepbound alone were 65 percent of total revenue in the first quarter of 2026, up from 56 percent for the full year 2025. This dive is written into a specific and unusual moment. The company reports the second quarter TOMORROW, 2026-08-05, on consensus EPS of $6.06 and revenue of $20.685B, after FIVE consecutive large beats (the most recent $8.55 against $6.97). Two things about that streak deserve stating plainly. First, the consensus $6.06 is 4.0% BELOW the $6.31 the company earned in the same quarter last year, on revenue expected to rise 33% — an arithmetic that only resolves through large charges, most plausibly acquired in-process R&D from up to $12 billion of pending acquisitions the 10-Q discloses. Second, the last beat was lower quality than it looked: the 10-Q attributes part of it to a favorable ONE-TIME adjustment to estimates for rebates and discounts, the effective tax rate fell to 16.4% from 20.2%, and there was no repeat of the prior-year $1.57B in-process charge. The data in this file is a quarter stale — the newest income statement ends 2026-03-31. The technical setup is the opposite of stretched: RSI 42.1, MACD negative, 3.1% below the 50-DMA, 9.7% below the 52-week closing high. Base fair value $1,220 at 27.0x FY2027 consensus is 9.3% above spot and 7.3% BELOW the street's $1,315.42 — we are the more cautious party. Own it; do not complete the purchase into a print you cannot handicap."”

Risk 6/10 · Growth 9/10

Open the full deep dive →

Think Pieces

All 18 pieces →

When something big happens, we map the blast radius — who's affected, by how much, over short, medium and long horizons.

The open-weight cyber shock: what Kimi K3-class agents break first, and who gets paid to fix itKimi K3 scored 32% on the UK-US exploit test against a 76% frontier average, and still nothing in it refused. Paired with open agent harnesses, that is enough to industrialize the known long tail: 14,090 new OSS vulnerabilities in two months, a 17,600-action autonomous breach, agentic ransomware. Second- and third-order consequences, six dated calls, the layers that get paid, and a verdict on BUG.From Petrodollars to Compudollars: four legs present or under construction, one inverted — and a numeraire that deflates 10-100x a yearLouis Gave and the voices we track are converging on one frame: a compute dollar replacing the petrodollar. A leg-by-leg test — the input, the pricing, the inverted recycling leg a The 800-volt data center: what Jordi Visser is actually talking aboutNVIDIA is rewiring the AI factory from 415V AC and 54V busbars to 800-volt DC, timed to the Kyber/Rubin Ultra generation. We decode Jordi Visser's 800V DC power-semi thesis: the ve

The Synthos Framework

The house view, assembled from everything the engine reads: the regime, the sectors, and where the strongest expert frameworks agree and collide. Read the Synthos Framework → · All expert frameworks →